NCT03444974: MATRIX-A

Addiction in Adolescence - Pathomechanisms and Treatment Evaluation

Status unknown NA Last updated 1 April 2019

What this trial tests

NA trial testing adapted treatment according to the MATRIX-A therapy in Substance Use Disorders in 450 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
28 February 2021

31 December 2021

Quick facts

Lead sponsor	Technische Universität Dresden
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	450
Start date	1 August 2018
Primary completion	28 February 2021
Estimated completion	31 December 2021
Sites	1 location across Germany

Drugs / interventions tested

• adapted treatment according to the MATRIX-A therapy

Conditions studied

• Substance Use Disorders — all drugs for Substance Use Disorders →
• Adolescent Behavior — all drugs for Adolescent Behavior →

Sponsor

Technische Universität Dresden — full company profile →

Who can join

Adults 12 to 17, any sex, with Substance Use Disorders or Adolescent Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the sociodemographic background as well as psychiatric comorbidities of adolescent substance users with substance use disorders. The study simultaneously evaluates biomarkers of stress and addiction, including long-term cortisol levels from hair samples and gene methylation in blood samples associated with substance use.

Our study also adapts, rolls out, and evaluates an evaluated multimodal treatment manual wich was originally intended for stimulant drug users (MATRIX). We adopt this manual to the needs and specifics of adolescents (MATRIX-A, A=adolescents) with substance use disorders of any substance, including cannabis, methamphetamine, and alcohol. Adolescents will receive group therapy sessions, individual therapy sessions, and medication if needed, while parents or professional caretaker will receive group sessions. Therapy outcomes will be examined in addition to parental distress and parenting skills.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Traumatic Events and Substance Use Disorders in Adolescents.
   Basedow LA, Kuitunen-Paul S, Roessner V, Golub Y. · · 2020 · cited 28× · PMID 32625122 · DOI 10.3389/fpsyt.2020.00559
2. Verbal learning impairment in adolescents with methamphetamine use disorder: a cross-sectional study.
   Basedow LA, Kuitunen-Paul S, Wiedmann MF, Ehrlich S, et al · · 2021 · cited 11× · PMID 33765981 · DOI 10.1186/s12888-021-03169-3
3. Coping motives mediate the relationship between PTSD and MDMA use in adolescents with substance use disorders.
   Basedow LA, Wiedmann MF, Roessner V, Golub Y, et al · · 2022 · cited 10× · PMID 36057623 · DOI 10.1186/s13722-022-00329-y
4. Comparing self-report and parental report of psychopathologies in adolescents with substance use disorders.
   Kuitunen-Paul S, Eichler A, Wiedmann M, Basedow LA, et al · · 2023 · cited 8× · PMID 34480628 · DOI 10.1007/s00787-021-01865-9
5. DNA methylation changes associated with cannabis use and verbal learning performance in adolescents: an exploratory whole genome methylation study.
   Wiedmann M, Kuitunen-Paul S, Basedow LA, Wolff M, et al · · 2022 · cited 6× · PMID 35933470 · DOI 10.1038/s41398-022-02025-6
6. Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use.
   Wiedmann M, Kuitunen-Paul S, Basedow LA, Roessner V, et al · · 2021 · cited 3× · PMID 35126190 · DOI 10.3389/fpsyt.2021.696133
7. Evaluation of the multimodal DELTA therapy for adolescents with substance use disorders: an exploratory pilot trial.
   Basedow LA, Kuitunen-Paul S, Wiedmann MF, Roessner V, et al · · 2023 · cited 2× · PMID 38234368 · DOI 10.3389/fpsyt.2023.1284342
8. Attenuated psychotic symptoms, substance use and self-reported PTSD in adolescence.
   Basedow LA, Wiedmann MF, Kuitunen-Paul S, Roessner V, et al · · 2023 · cited 1× · PMID 37010565 · DOI 10.1080/20008066.2023.2193327